Last reviewed · How we verify
TTVA
TTVA is a vaccine that induces an immune response against the SARS-CoV-2 virus.
TTVA is a vaccine that induces an immune response against the SARS-CoV-2 virus. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | TTVA |
|---|---|
| Sponsor | CanSino Biologics Inc. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
TTVA works by stimulating the body's immune system to produce antibodies and immune cells that can recognize and fight the SARS-CoV-2 virus. This is achieved through the use of a viral vector that carries a gene from the SARS-CoV-2 virus, which is then expressed by cells in the body and triggers an immune response.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTVA CI brief — competitive landscape report
- TTVA updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI